Theileria parva is a tick-transmitted apicomplexan parasite that infects cattle and African buffalo. In cattle, it causes a fatal lymphoproliferative disease called East Coast fever. The polymorphic immunodominant molecule (PIM) is expressed by two stages of the parasite: the sporozoite, which is inoculated by the tick to infect mammalian lymphocytes, and the schizont, the established intralymphocytic stage. Here, we demonstrate that monoclonal antibodies (MAb) to PIM can reduce the ability of sporozoites to infect bovine lymphocytes in vitro. This reduction appears to be due to blocking of sporozoite attachment by binding of the MAb to several regions of PIM. Interestingly, one MAb, which recognizes an epitope in the central variable region of PIM, did not inhibit sporozoite infectivity. We also demonstrate that PIM antigen, as a recombinant molecule, can also reduce sporozoite infectivity in vitro by blocking both attachment and internalization of sporozoites. Electron microscopic studies showed that PIM is present in microspheres below the sporozoite surface and is transported to the parasite surface soon after contact with bovine lymphocytes. The results suggest that at least two sporozoite molecules, PIM and the previously described p67, are involved in the entry of T. parva into mammalian lymphocytes.
T
heileria parva is an apicomplexan protozoan parasite that causes East Coast fever, a fatal lymphoproliferative disease of cattle in eastern, central, and southern Africa. The infective stage of the parasite, the sporozoite, is transmitted through the saliva of ticks of the species Rhipicephalus appendiculatus during feeding. After inoculation, the sporozoites bind to and enter the host's lymphocytes and mature intracellularly into a multinucleated schizont stage. The infected cells become transformed, with the schizonts dividing in synchrony with the cell, which leads to rapid clonal expansion and severe pathology and death in the host.
The ability of T. parva sporozoites to transform target cells is specific for the host species (only cells from cattle and African buffalo) and for the cell type (only T and B lymphocytes and null cells) (1) . Unfortunately, not enough is known about the mechanism of sporozoite entry and the molecular nature of sporozoitelymphocyte recognition to help in devising new control strategies, but several studies have furnished information about those processes. Sporozoites of T. parva are quite different from those of other apicomplexan parasites, especially the malaria organisms. T. parva sporozoites are nonmotile, they lack micronemes, and they can attach to and invade host cells in any orientation (2) . Using electron microscopy (EM) to assess sporozoite entry, there is clear evidence that the process is dependent on the host cell actin cytoskeleton (3) and is mediated by both parasite and host cell signal transduction pathways (4) . This suggests a complex mechanism that needs an active sporozoite, as well as an active host cell.
In vitro binding and entry studies with sporozoites have revealed some facts about potential receptor molecules on the lymphocyte and potential ligands on the sporozoite that mediate the adhesion process. Again, using electron microscopy to monitor infected cells, it was observed that monoclonal antibodies (MAb) specific for bovine major histocompatibility complex (MHC) class I and ␤2-microglobulin molecules prevented the entry of sporozoites into their target cells (5) . However, MHC class I is expressed on all nucleated cells in mammals, including macrophages and neutrophils, cells which are not infected with T. parva (1) . This suggests that MHC class I is only part of a receptor complex or one of several receptors. In a systematic search for additional sporozoite receptors by measuring inhibition of sporozoite binding using flow cytometry, one MAb to CD45R that inhibited adhesion was identified, suggesting a role for CD45R in the binding process (6) . Somewhat paradoxically, the same study showed that complete removal of surface CD45R with a protease while leaving MHC class I molecules intact on the surface enhanced sporozoite binding, which suggests that CD45R is not a receptor but might inhibit sporozoite binding by steric hindrance or another mechanism. These observations provide further indications that sporozoite-lymphocyte adhesion is much more complex than just a specific interaction between one host cell receptor and one parasite ligand.
Antibodies to the main sporozoite surface antigen, p67, also neutralized sporozoite entry (7, 8) . Since purified p67 could inhibit binding (5) , the molecule can be considered the sporozoite ligand. Because antibodies to p67 neutralized sporozoite entry in an in vitro culture assay, the molecule has been the target of several vaccine studies. Immunization with recombinant p67 provided cattle with immunity to homologous challenge (9) . This was confirmed in field studies (10) , although the observed 50% reduction in disease severity suggests that improvements are required before a p67-based vaccine can be considered an effective control measure. Recent studies on a T. parva isolate from Zambia (T. parva Chitongo) with low virulence and a reduced capacity to infect bovine lymphocytes (11) suggested that a second adhesin might exist. Sporozoites from this isolate bound only T lymphocytes of the CD8 ϩ phenotype (12) , in contrast to sporozoites from other, more virulent stocks that bind several lymphocyte phenotypes, including B cells and other CD8
Ϫ lymphocytes (1). However, this isolate has the same p67 sequence as the more virulent isolates, suggesting that specificity for the target cell must be mediated by another adhesin molecule.
In parallel to the search for the lymphocyte receptor, neutralization studies with MAb to other sporozoite molecules identified the polymorphic immunodominant molecule (PIM) as possibly having a role in adhesion (13) . PIM is the predominant T. parva protein recognized by the sera of infected cattle and by a series of MAb developed to type different stocks of T. parva (14, 15) . The size of PIM varies greatly among and within stocks of T. parva, as evidenced by the range of M r s estimated by polyacrylamide gel electrophoresis, from 62,000 to 112,000 (15) . Sequence analysis has shown that the single-copy gene encoding PIM consists of conserved termini flanking a variable central region (13, 16) . In the version of PIM expressed by T. parva Muguga, the predicted lengths of these regions are 71, 201, and 208 amino acids, respectively. The size variation is due to differences in the length of the central region. Anti-PIM antisera and MAb react predominantly with the amino-terminal and variable central regions of the molecule (17) .
Due to the importance of the sporozoite entry process as a point of strategic immunological intervention in T. parva infection, further examination of the role of PIM in this process was undertaken. Specifically, we examined the anti-PIM MAb and recombinant PIM in an assay based on electron microscopy to determine the stage of parasite entry at which inhibition occurs. We also employed the MAb and bovine antisera to determine the locations of PIM in sporozoites and schizonts.
MATERIALS AND METHODS
Monoclonal antibodies and bovine anti-PIM antiserum. The JK series of MAb was produced from a mouse that had been inoculated on three occasions with a recombinant version of PIM (Muguga PIM fused to glutathione S-transferase [GST-PIM]) using a method previously described (13) . The other MAb used in these experiments have been described previously (17) (18) (19) (20) (21) , and the relevant data are presented in Table 1 .
The bovine antiserum to PIM was derived from animal BJ345, which had been inoculated with the NS1-PIM bacterial recombinant protein (described below) on three occasions at monthly intervals. Each dose consisted of 2 ml of the NS1-PIM preparation supernatant, which is equivalent to the Nonidet P-40 soluble fraction of 300 mg (wet weight) of bacteria. The protein preparations were emulsified in 3% saponin immediately prior to inoculation. All antigen preparations were administered subcutaneously on the side of the neck, and the antiserum was obtained 2 weeks after the final inoculation. The antiserum was observed to react in immunoblot analysis with PIM antigens from several stocks of T. parva (results not shown).
Bacterial PIM fusion proteins. The construction of a plasmid expressing GST-PIM has been described previously (13) . The recombinant plasmid allows the expression of all except the initial 2 amino acids of the PIM fused at the PIM amino terminus to the carboxyl terminus of GST.
A second recombinant PIM molecule (NS1-PIM) was produced in which the first 81 amino acids of the NS1 protein of influenza A virus plus Met-Asp-His-Met-Leu from polylinker DNA was followed by all except the initial two amino acid residues of the Muguga PIM molecule. The NS1-PIM antigen for inoculation was prepared from a 4-liter culture. The bacteria were harvested and suspended in cold glycine buffer (50 mM glycine, 2 mM EDTA, pH 8.0) and disrupted in a bead beater. After centrifugation at 13,000 ϫ g for 30 min, the bacterial pellet was washed once with glycine buffer and resuspended in 100 ml glycine buffer-0.1% Nonidet P-40 (NP-40). The sample was kept at 4°C for 1 h before centrifugation as described above. The supernatant was recovered and was stored at Ϫ70°C until it was used for inoculation.
IFA and COS cell analysis. Immunofluorescence assays (IFA) were performed by fluorescence microscopy using T. parva Muguga-infected lymphocytes fixed in suspension with acetone and formaldehyde, as described previously (22) . Immunofluorescent-antibody staining of COS cells was performed by transiently transfecting the cells, as previously described (13), with plasmids containing cDNA encoding full-length PIM (13) or the KN104 class I MHC molecule (23) .
Electron microscopy. Bovine peripheral blood lymphocytes (PBL) were recovered from defibrinated blood subjected to centrifugation through a Ficoll-Hypaque (Pharmacia, Sweden) density gradient to yield a population of mononuclear cells with less than 0.3% monocytes (24) . Freshly isolated T. parva Muguga sporozoites from infected tick salivary glands were incubated with the PBL for 5, 15, or 30 min. The samples were fixed by adding 0.1 M sodium phosphate buffer, pH 7.3, containing 0.02% glutaraldehyde, 4% paraformaldehyde, 0.4% picric acid, and 1.0 mM calcium chloride to an equal volume of the PBL-sporozoite suspension. For postembedding labeling, the samples were processed into Lowicryl K4M resin (Chemische Werke Lowi, Germany) as previously described (25) . Ultrathin sections were prepared, and immunoelectron microscopy was performed by previously described methods (26) . For preembedding labeling experiments, the fixed cell-sporozoite suspensions were washed three times in sodium phosphate buffer and incubated for 30 min in sodium phosphate buffer containing 0.02 M glycine. The samples were washed once in sodium phosphate buffer containing 5% bovine serum albumin, after which the cells were incubated in MAb or polyclonal antisera (diluted 1:100) for 30 min at 22°C. The cells were again washed three times in sodium phosphate buffer and then incubated in either goat anti-mouse immunoglobulin (GAM) coupled to colloidal gold (for samples labeled with MAb) or the anti-bovine immunoglobulin MAb IL-A2 (27) for 30 min, followed by GAM-colloidal gold for 30 min (for samples labeled with bovine antisera). The samples were washed three times in sodium phosphate buffer before being fixed in 0.1 M cacodylate buffer containing 2% glutaraldehyde and processed into Epon-araldite by conventional techniques. All samples were examined with a Zeiss EM 10 A electron microscope.
Sporozoite neutralization culture assay. The in vitro culture assay to determine the effects of heat-inactivated bovine anti-PIM antisera or MAb on sporozoite infectivity has been described previously (8) . The results are expressed as the percentage of cells containing schizonts, determined by examination of Giemsa-stained cytospin smears 10 to 14 days after infection of bovine PBL.
EM assay. The EM assay to measure sporozoite inhibition has been described previously (28) . In brief, the MAb, as a 1/20 dilution of ascites, were added to sporozoite suspensions. After 5 min incubation at 37°C, bovine PBL prepared from an uninfected animal were added, and the mixture was incubated for a further 30 min. The samples were then fixed and processed for EM to determine the infectivity of the sporozoites. The effects of each MAb on both the attachment index and the internalization index were determined. The attachment index is the percentage of lymphocytes with sporozoites either attached to the surface or internalized. The internalization index is the number of fully internalized sporozoites expressed as a percentage of the total number of sporozoites (attached to the surface or internalized) observed. In each sample, 300 to 500 lymphocytes were counted.
When the effect of the GST-PIM fusion protein was determined, the assay was similar to that described above except that the GST-PIM or GST protein was incubated with PBL for 5 min before the addition of sporozoites. The mixture was incubated for a further 30 min before fixing and processing.
In some experiments, control samples contained normal mouse serum or ascitic fluid at a 1:10 dilution, while the remainder had no MAb or fusion protein. The normal mouse serum or ascitic fluid had no effect on infectivity. The results for the control samples were similar to those reported previously (28) . Statistical analysis of the data was performed using Student's t test, with a P value of 0.05 as the cutoff point for significance.
Immunoblotting. Polyacrylamide gel electrophoresis and immunoblotting were carried out as previously described (15), with each lane containing 10 5 cell equivalents of lysate. The T. parva-infected lymphocyte lines have been described previously (15) .
Pepscan analysis. The reactivity of MAb JK12.2 with a series of peptides representative of the predicted sequence of the Muguga PIM without the initial 5 amino acids was performed as previously described (17) . The peptides were 12 residues long and overlapped the preceding and subsequent peptides by 7 residues. The MAb was assayed as ascites diluted 1:5,000.
Experiments involving animals. The MAb and bovine antiserum were produced at the International Livestock Research Institute (ILRI), Nairobi, Kenya, using procedures approved by the Institutional Animal Care and Use Committee. The ability of MAb IL-S36.5 to reduce the infection of bovine PBL by sporozoites in an in vitro culture assay has been reported previously (13) . We report here that MAb IL-S32.3, IL-S34.3, and IL-S40.2 also reduced sporozoite infectivity by 100%, 100%, and 96%, respectively, in the culture assay. Thus, the inhibitory abilities of these MAb appear to be independent of the region of PIM recognized by the MAb. This assay measures the ability of MAb to affect infectivity by determining the number of infected lymphocytes in cultures 10 to 14 days after exposure to sporozoites in the presence of the MAb. The assay does not determine at which stage of the binding and internalization process the inhibition occurs.
RESULTS

Anti-PIM
We used an alternative method based on electron microscopy that measures both the attachment of sporozoites to lymphocytes (the attachment index, expressed as the percentage of lymphocytes with attached or internalized sporozoites) and the subsequent internalization of the sporozoites (the internalization index, expressed as the percentage of sporozoites internalized out of the total number of sporozoites, attached or internalized). When analyzed in this assay, all four MAb clearly reduced the attachment of sporozoites to the lymphocytes, as indicated by the reduced attachment index (Table 2) . However, the MAb did not affect the subsequent internalization of those sporozoites that did attach. For three of the anti-PIM MAb, the internalization index was similar to that of the control MAb, whereas that of MAb IL-S34.3 was significantly greater, which suggests that this MAb may facilitate sporozoite internalization.
Recombinant PIM reduces sporozoite infectivity. To obtain more evidence that PIM is involved in sporozoite entry, we examined the inhibitory ability of purified recombinant PIM protein in the EM assay. The mean results from three experiments are shown in Table 3 . The presence of the GST-PIM fusion protein had a significant effect on both the attachment index and the internalization index. No reduction was observed with similarly prepared GST alone, suggesting that the reduction was not due to the GST component of the fusion protein or to minor bacterial contaminants remaining in the fusion protein preparation. The effect of GST-PIM was also dose dependent, with greater reduction observed at a GST-PIM concentration of 2 g/ml than at 1 g/ml under the in vitro conditions used. A second set of experiments was conducted to include GST-PIM 5=, a fusion protein consisting of GST fused to the initial amino acids 2 to 75 of PIM. Immunoblot analysis had revealed that GST-PIM 5= had an M r of about 38,000 compared to GST-PIM (116,000) and GST alone (28,000) (17) . Thus, GST-PIM 5= was much closer in size to the control GST molecule. Reduction of sporozoite attachment and internalization was observed with both PIM-containing recombinant proteins (Table 3) .
Lack of inhibition with a MAb specific for part of the central region of PIM. The MAb used in the previous experiments were produced from mice inoculated with T. parva-infected lymphocytes. We generated another series of MAb from a mouse that had received the GST-PIM fusion protein. One of the MAb (JK12.2) was shown to react with the surfaces of COS cells transfected with cDNA encoding PIM (Fig. 1) , indicating that MAb JK12.2 recognizes PIM in an unfixed and undenatured state. However, when used in in vitro culture assays, MAb JK12.2 failed to reduce sporozoite infectivity. Interestingly, while the control culture (no MAb) had 10% infected cells and the culture with the blocking anti-p67 MAb 23F had 0%, the anti-PIM MAb JK12.2 resulted in increased infectivity, with cultures having 17% infected cells. This was surprising, as it had been shown previously that antisera from rats inoculated with the GST-PIM interfered with sporozoite entry (13) .
One explanation for the lack of inhibition observed with MAb JK12.2 is that it binds very weakly to the native PIM. To examine this, we compared the IFA endpoint titer of the MAb JK12.2 sample on fixed schizont-infected cells to the titers obtained with the neutralizing MAb samples. The reactivity of the MAb JK12.2 sample with PIM was detectable at a dilution of 1:62,500 compared to 1:62,500, 1:312,500, and 1:312,500 for the samples of the neutralizing MAb 4, 5, and IL-S40.2, respectively. These results suggest that the failure of MAb JK12.2 to reduce sporozoite infectivity is not due to lack of affinity for the PIM antigen.
An alternative explanation is that MAb JK12.2 recognizes an epitope of PIM that is not involved in sporozoite attachment to the lymphocyte. The MAb was examined in immunoblot analysis against several T. parva-infected cell lines known to express different forms of PIM, all of which are recognized by neutralizing MAb (15) . MAb JK12.2 reacted with the PIM antigens from only two parasite stocks: T. parva Muguga and a buffalo-derived stock, 7014 (Fig. 2) . This range of reactivity has not been observed with the other neutralizing MAb, indicating that MAb JK12.2 is specific for an epitope not recognized by the other MAb.
To locate the MAb JK12.2 epitope more definitively, we analyzed its reactivity with a series of overlapping peptides representing the Muguga PIM protein. MAb JK12.2 reacted with two pairs of peptides, both of which are located in the central variable region ( Fig. 3) . The overlapping sequences in the peptide pairs are DTP DQPV and PDSPDQP. A putative epitope sequence, DXPDQP, is not found elsewhere in the PIM sequence of T. parva Muguga, and none of the neutralizing MAb recognize these peptides, both observations supporting the contention that MAb JK12.2 is specific for an epitope not recognized by the neutralizing MAb. Localization of the PIM antigen in sporozoites. The anti-PIM MAb 2, 4, 5, IL-S36.5, IL-S40.2, and JK12.2 and a bovine anti-PIM antiserum raised against recombinant GST-PIM (BJ345) were used in electron microscopy to locate PIM in sporozoites and schizonts. The experiments consisted of both preembedding labeling of fixed whole sporozoites to indicate surface localization and postembedding labeling of sections of sporozoites and infected lymphocytes to detect both surface-associated and intracellular molecules.
In preembedding labeling experiments, only MAb 5 reacted with the sporozoite surface, but only with about 10% of the sporozoites in any given sample (Fig. 4a) . None of the other MAb or antiserum BJ345 reacted with the surfaces of the sporozoites (results for MAb 4 are shown in Fig. 4c) .
In postembedding labeling, the anti-PIM MAb and antiserum BJ345 produced similar patterns of reactivity. PIM was detected associated with the electron-dense microspheres just below the surface of the sporozoite before and during internalization (Fig.  4b and d and 5a and b) . Soon after sporozoite entry (Fig. 5c) , the PIM antigen appears on the surface of the parasite, as the microspheres discharge their contents. After 2 days of culture, the PIM antigen is seen associated with the surface of the intracellular schizont (Fig. 5d) . No labeling was observed with a control irrelevant MAb or with a bovine control serum. These observations indicate that PIM is discharged from the microspheres very soon after sporozoite entry and is then associated with the surface of the mature schizont.
DISCUSSION
The experiments presented here were conducted to explore the role of PIM in the sporozoite entry process. The electron microscopy observations clearly show PIM in the microspheres of mature sporozoites. The microspheres of T. parva are believed to translocate molecules to the sporozoite surface in the absence of an endoplasmic reticulum (29) . The p67 molecule is detectable in the microspheres of developing sporoblasts and to a lesser extent in mature sporozoites, and concurrent labeling of p67 in micro- spheres and on the parasite surface was observed (30) . It is not clear whether PIM is also expressed on the sporozoite surface. In our experiments, only MAb 5 reacted with the surface of the sporozoite and then with only about 10% of the sporozoites in any sample. A similar proportional result with MAb 5 had been recorded in earlier unpublished experiments (P. Webster, personal communication). One possible explanation is that PIM is expressed on the surfaces of sporozoites at a certain developmental stage, which comprise only 10% of the population from infected salivary glands, and in a form recognized only by MAb 5 among the antibodies examined. Alternatively, MAb 5 may cross-react with another sporozoite protein otherwise unrelated to PIM. It has been reported that another anti-PIM MAb, MAb 8, shares an epitope with a 150-kDa sporozoite protein located in the microspheres (31) .
As the parasite enters and the microspheres discharge their contents, PIM is seen to be associated with the parasite surface. This, together with the evidence discussed below, suggests that PIM is involved in mediating the establishment of the parasite within the lymphocyte. The molecule remains expressed and associated with the parasite surface in established lymphocytes, suggesting that it has an essential function in the mature schizont.
The in vitro culture experiments presented here confirm earlier results showing that anti-PIM antibodies can affect the establishment of infected cell lines (13) . The MAb used in the studies reported here were selected because they react with different regions of the PIM antigen. As they all reduced infection, we could not, as we had hoped, implicate a specific region of the antigen in the infective process.
The same MAb were tested in the EM assay and caused a significant decrease in the attachment index. As the internalization index was unaffected by the presence of the MAb, the initial impression is that PIM is involved only in attachment. This is difficult to explain, given the abundance of p67 and the scarcity of detectable PIM on the parasite surface. An alternative explanation is based on the assumption that sporozoites can make contact with the lymphocyte surface via a primary low-affinity ligand-receptor pair consisting of p67 and its receptor on lymphocytes but detach if tight membrane apposition and internalization, mediated by a second, high-affinity ligand-receptor pair, do not ensue. Once the second interaction has been initiated, internalization proceeds normally, possibly in a number of steps involving a series of molecular mechanisms, and the internalization index is unaffected. In this light, the results suggest that PIM reacts with a putative receptor to initiate or sustain internalization. If insufficient MAb are in the vicinity of the binding site, internalization proceeds and is accelerated by the extrusion of more and more PIM onto the surface of the parasite. This hypothesis assumes that the first contact between host cell and sporozoite is initiated by a low-affinity ligand-receptor pair but is weak enough to allow antibodies or other molecules from the environment to interact with host cell and parasite surface components before the second, high-affinity interaction and the ensuing internalization take place.
Preincubation with recombinant PIM caused a decrease in both the attachment and internalization indices. We assume that the recombinant molecule attached to the putative PIM receptor prior to the addition of sporozoites. The decrease in the attachment index may be the result of interference of the putative highaffinity interaction and/or the ensuing internalization described above due to insufficient PIM-PIM receptor interactions. The decrease in the internalization index suggests that the invasion process can be stopped or significantly slowed, presumably due to occupation of PIM receptors by the recombinant protein. Under the conditions used in the current experiments, blocking the receptor (with recombinant PIM) was more efficient than blocking PIM on the sporozoite (with antibody) to prevent high-affinity attachment. A number of factors could be responsible for this, including the smaller size and thus higher diffusion rate of recombinant PIM compared to antibody, an affinity between recombinant PIM and its receptor higher than the affinity between antibody and PIM, or a higher molar concentration of recombinant PIM than of antibody. Another factor could be better accessibility: the receptor (the target of the PIM recombinant protein) is available for binding before the weak interaction between cell and parasite, but PIM (the target of the MAb) appears only after the weak interaction and is thus less susceptible to interference.
The results demonstrating the inability of MAb JK12.2 to reduce infectivity are valuable in that they support the idea that the effect on sporozoite entry shown by the other MAb is due to disruption of a specific ligand-receptor interaction involving PIM and not, for example, steric hindrance of a nearby molecule. The lack of neutralization shown by MAb JK12.2 may be due to weak reactivity with the native protein compared with the recombinant molecule, although the similarity of the IFA titers on infected cells obtained with this MAb and those of the neutralizing MAb, and its reactivity with transfected cells expressing PIM, suggest otherwise. Peptide and immunoblot analyses showed that MAb JK12.2 recognizes an epitope not recognized by any of the neutralizing MAb. Thus, an alternative explanation is that MAb JK12.2 reacts with an epitope that is distant from the site of interaction between PIM and its receptor.
In summary, we believe that these experiments implicate PIM in the infective process in the events subsequent to initial contact. Several issues remain to be resolved, such as the identity of the PIM receptor, the reason for the extensive polymorphism of PIM, and whether PIM can be used, in combination with p67, to prevent infection in vivo. It would also be of interest to determine if the homologues of PIM found in other Theileria species, such as the TaSP protein of Theileria annulata (32) and similar molecules in Theileria lestoquardi and another pathogenic Theileria species (33) , are involved in the sporozoite entry process.
